{"id":398655,"date":"2020-12-14T01:03:13","date_gmt":"2020-12-14T06:03:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398655"},"modified":"2020-12-14T01:03:13","modified_gmt":"2020-12-14T06:03:13","slug":"novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/","title":{"rendered":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma"},"content":{"rendered":"

<\/p>\n

\nNovocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma\n<\/p>\n

ST. HELIER, Jersey–(BUSINESS WIRE<\/a>)–
\nNovocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland.\n<\/p>\n

\n\u201cWe are extremely pleased that Switzerland has established national reimbursement for Optune,\u201d said Thomas Hefti, Vice President Europe and Emerging Markets (EMEA). \u201cAccess to our therapy continues to grow throughout the world, demonstrating health insurers\u2019 increasing recognition of Optune.\u201d\n<\/p>\n

\n\u201cNational reimbursement of Optune for newly diagnosed GBM patients in Switzerland represents an incredible effort by our team to expand access to our therapy as well as an increased understanding of the benefits of our therapy among health insurers,\u201d said Pritesh Shah, Novocure\u2019s Chief Commercial Officer. \u201cWe are proud of this accomplishment and will continue working diligently to expand access to GBM patients who may benefit.\u201d\n<\/p>\n

About Optune
\n
<\/b>Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to the region of the tumor.\n<\/p>\n

\nTumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells with specific membrane properties. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with GBM and in the U.S. for MPM, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types \u2013 including some of the most aggressive forms of cancer.\n<\/p>\n

Approved Indications
\n
<\/b>Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).\n<\/p>\n

\nOptune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.\n<\/p>\n

\nFor the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.\n<\/p>\n

Important Safety Information
\n
Contraindications
\n
<\/b>Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.\n<\/p>\n

\nUse of Optune for GBM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.\n<\/p>\n

\nDo not use Optune for GBM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.\n<\/p>\n

Warnings and Precautions
\n
<\/b>Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure\u00ae.\n<\/p>\n

\nThe most common (\u226510%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.\n<\/p>\n

\nThe most common (\u226510%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.\n<\/p>\n

\nIf the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune treatment.\n<\/p>\n

\nDo not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.\n<\/p>\n

About Novocure
\n
<\/b>Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division. Novocure\u2019s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.\n<\/p>\n

\nHeadquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com<\/a> or follow us at www.twitter.com\/novocure<\/a>.\n<\/p>\n

Forward-Looking Statements
\n
<\/b>In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure\u2019s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as \u201canticipate,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve\u201d or other words and terms of similar meaning. Novocure\u2019s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201213005052\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
Gabrielle Fernandes
\n
gfernandes@novocure.com
\n<\/a>
603-206-7047\n<\/p>\n

Media:
\n<\/b>
Jaclyn Stahl
\n
jstahl@novocure.com
\n<\/a>
212-767-7516\n<\/p>\n

KEYWORDS:<\/b> Jersey Switzerland Europe Germany Austria<\/p>\n

INDUSTRY KEYWORDS:<\/b> Insurance Surgery Medical Devices Professional Services Biotechnology Radiology Health Pharmaceutical Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland. \u201cWe are extremely pleased that Switzerland has established national reimbursement for Optune,\u201d said Thomas Hefti, Vice President Europe and Emerging Markets (EMEA). \u201cAccess to our therapy continues to grow throughout the world, demonstrating health insurers\u2019 increasing recognition … <\/p>\n

Continue reading “Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland. \u201cWe are extremely pleased that Switzerland has established national reimbursement for Optune,\u201d said Thomas Hefti, Vice President Europe and Emerging Markets (EMEA). \u201cAccess to our therapy continues to grow throughout the world, demonstrating health insurers\u2019 increasing recognition … Continue reading "Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T06:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma\",\"datePublished\":\"2020-12-14T06:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/\"},\"wordCount\":1159,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/\",\"name\":\"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-14T06:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/","og_locale":"en_US","og_type":"article","og_title":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk","og_description":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland. \u201cWe are extremely pleased that Switzerland has established national reimbursement for Optune,\u201d said Thomas Hefti, Vice President Europe and Emerging Markets (EMEA). \u201cAccess to our therapy continues to grow throughout the world, demonstrating health insurers\u2019 increasing recognition … Continue reading \"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T06:03:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma","datePublished":"2020-12-14T06:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/"},"wordCount":1159,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/","name":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-14T06:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201213005052r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novocure-announces-national-reimbursement-in-switzerland-for-optune-in-combination-with-temozolomide-for-the-treatment-of-newly-diagnosed-glioblastoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novocure Announces National Reimbursement in Switzerland for Optune\u00ae in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}